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Uroplakin II outperforms uroplakin III in diagnostically challenging settings
Aims: We performed a head-to-head comparison of
an antibody against uroplakin III (UP3) and a new
uroplakin II (UP2) antibody that remains untested in
diagnostically challenging settings.
Methods and results: We immunostained high-grade
bladder neck carcinomas (n = 35), high-grade upper
tract urothelial carcinomas (UC) and renal carcinomas
(n = 85), metastases of UC (n = 30) and a multicancer
tissue microarray (n = 88) for UP3 and UP2, and
scored staining intensity and proportion. UP3 showed
membranous plaque-like expression, while UP2 stain-
ing showed both membranous and cytoplasmic positiv-
ity. Significantly greater intensity (P = 0.003) and
proportion (P = 0.03) of staining was noted for UP2
among bladder neck lesions, with UP2 staining show-
ing greater sensitivity (63% versus 19%) and similar
specificity (95% versus 100%) for UC over prostate car-
cinoma (P = 0.02). Among upper tract lesions, UP2
staining showed greater intensity and proportion than
UP3 (both P < 0.001), including improved sensitivity
(68% versus 23%) and equal specificity (both 100%)
for UC (P = 0.006). Among UC metastases, UP2 stain-
ing showed greater intensity and proportion (both
P < 0.001) with higher sensitivity (73% versus 37%,
respectively, P = 0.001). Of 88 additional cases tested,
no non-urothelial cases stained for either UP.
Conclusions: The UP2 antibody outperforms the UP3
antibody, including in diagnostically challenging set-
tings, and is a useful addition to the armamentarium
of biomarkers for UC.
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Introduction
The urothelial lining of the pelvicalyceal mucosa of the
kidney, the ureter, the urinary bladder and the proxi-
mal urethra comprises a stratified epithelium of five to
seven cell layers; these strata proceed from a basal cell
population, through intermediate cells, to an umbrella
cell population lying immediately at the luminal sur-
face. The latter umbrella cells produce specialized uro-
thelial plaques composed of uroplakins Ia, Ib, II and
IIIa, which occupy the luminal surface of the epithe-
lium, and cytoplasmic vesicles from where they may
be cycled to the surface during the expansion and con-
traction cycle of the urothelium, as reviewed recently.1
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Conventional markers of urothelial carcinomas
(UC) include p63, high molecular weight cytokeratin
and cytokeratin 5/6, also expressed in squamous
lesions, and coexpression of cytokeratins 7 and 20,
which is neither highly sensitive nor specific.
Improved markers of urothelial histogenesis include
GATA3 and S100P.2 However, recent studies have
demonstrated significant rates of GATA3 positivity
in primary and metastatic ductal and lobular carci-
nomas of the breast, cutaneous basal cell carcino-
mas, trophoblastic neoplasms, yolk sac tumours,
mesotheliomas, salivary gland carcinomas and pan-
creatic ductal carcinomas,3 prompting greater cir-
cumspection regarding its specificity. Also, significant
positivity for S100P has been shown in pancreati-
cobiliary lesions.4 Several years ago, staining for
uroplakin III (UP3) was introduced as a highly spe-
cific and moderately sensitive marker of urothelial
carcinoma, showing ‘plaque-like’ membranous
expression.5 Sensitivities reported were in the range
of 50–60%,5,6 although we and others have
observed lower sensitivities,7,8 especially in invasive
or metastatic lesions.8,9 None the less, this marker
shows exquisite specificity, with no staining observed
in hundreds of non-urothelial lesions.5,8
Recently, a new monoclonal antibody has been
raised against another uroplakin, uroplakin II (UP2).
UP2 is a smaller, related protein (15 versus 47 kDa),
which dimerizes with uroplakin Ia rather than Ib,
contains a more limited cytoplasmic domain, and is
not glycosylated.1 Preliminary comparisons using pri-
mary urothelial carcinomas and other cancers sug-
gest that UP2 has greater sensitivity than UP3, with
preserved specificity;10 these observations have not
been tested in relevant diagnostic settings where iden-
tification of UC, as opposed to other lesions in the dif-
ferential, may result in fundamental therapeutic
differences. Thus, we tested UP2 and UP3 antibodies
‘head-to-head’ in diagnostically challenging settings:
(i) high-grade carcinomas involving the bladder neck,
(ii) high-grade carcinomas of the upper urothelial
tract and (iii) metastatic UC.
Materials and methods
C O H O R T S T E S T E D
A retrospective cohort of archival tissues was assem-
bled for testing in three diagnostically challenging
settings. The first was a cohort of whole sections of
high-grade UC and high-grade prostatic adenocarcino-
mas (PCa) involving the bladder neck (n = 35). The
second cohort included a tissue microarray cohort, pre-
viously assembled and reported11 to comprise aggres-
sive (>pT3) high-grade carcinomas of the upper tract
(n = 70), plus whole tissue sections of upper tract UC
(n = 10) and collecting duct carcinomas (CDC) (n = 5).
The third cohort included whole sections of metastatic
deposits of UC (n = 30). Finally, additional descriptive
studies were performed on whole sections of rare vari-
ants of UC (n = 30) and a tissue microarray (TMA) of
representative examples of neoplasms of varying histol-
ogies (n = 88), including adenocarcinomas (n = 25),
neuroendocrine tumours (n = 15), squamous cell car-
cinomas (n = 10), renal and germ cell tumours (each
n = 6), salivary gland and thyroid tumours (each
n = 5), other carcinomas (n = 4), paragangliomas
(n = 3), urothelial carcinomas (n = 2) and other
(n = 7). These cases were selected across a wide ana-
tomical distribution, including respiratory (n = 15),
gastrointestinal (n = 25), genitourinary and gynaeco-
logical (n = 36) and endocrine (n = 12) organs.
I M M U N O H I S T O C H E M I S T R Y
For both UP2 (clone BC21 prediluted; Biocare Medical,
Concord, CA, USA) and UP3 (clone AU-1 prediluted;
Cell Marque, Rocklin, CA, USA), immunohistochemis-
try (IHC) was performed on a Benchmark Ultra
(Ventana, Tucson, AZ, USA) autostainer in the
Cedars-Sinai Medical Center Clinical Immunohisto-
chemistry core facility. IHC used integrated
heat-induced epitope retrieval in high pH CC1 buffer,
with visualization using the Ultraview DAB detec-
tion system (Ventana) and Mayer’s haematoxylin
counterstain.
Figure 1. Representative examples of UP2 and UP3 immunostaining. A–C, A high-grade upper tract urothelial carcinoma (UC) (A), shows
2+ intensity and multifocal (2+) staining for UP3 (B), and intense (3+), diffuse (3+) UP2 expression (C). D–F, A Gleason score 4+5 adenocar-
cinoma of the bladder neck with diffuse prostate-specific membrane antigen positivity, (D), shows negative staining for UP3 (E), and intense
(3+), focal (1+) UP2 expression (F). This was the only case of aberrant expression of UP2 in >160 non-urothelial carcinomas tested. G–H, A
duodenal metastasis in a patient with a long history of UC shows poorly differentiated UC with extensive lymphatic involvement (G) shows
negative staining for UP3 (H), and moderate (2+), multifocal (2+) UP2 expression (I). K, A bladder UC variant with ‘villoglandular’ morphol-
ogy (exophytic component) and subjacent invasive plasmacytoid UC morphology (J) shows moderate (2+), multifocal (2+) UP3 expression in
the villoglandular areas and negative UP3 expression in plasmacytoid areas (K). UP2 staining is intense (3+) and diffuse (3+) in both compo-
nents (L).
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E V A L U A T I O N O F I M M U N O H I S T O C H E M I S T R Y
Immunostain intensity and proportion were scored
independently by two pathologists (S.C.S. and
S.K.M.), with discordances resolved in consensus with
a senior genitourinary pathologist (M.B.A.). Intensity
was scored as 0 (negative), 1 (weak), 2 (moderate)
and 3 (intense), while proportion was scored as 0
(negative), 1 (focal), 2 (multifocal) and 3 (diffuse).
Focal staining was defined arbitrarily as the mini-
mum proportion that would reasonably considered as
positive if it were encountered prospectively in a diag-
nostically challenging case, and positive stain was
defined as focal or greater. Statistical differences in
paired distributions of UP2 and UP3 staining intensity
and proportion were tested by the Wilcoxon
matched-pairs test using PRISM (GraphPad Software,
La Jolla, CA, USA), and differences in paired binary
distributions of positive and negative cases were
tested by McNemar’s test using SPSS version 22
(IBM, Redmond, WA, USA).
Results
S T A I N P A T T E R N
Consistent with previous reports, immunostaining for
UP3 showed membranous, frequently ‘plaque-like’
positivity or pericellular membranous positivity, while
immunostaining for UP2 showed diffuse membranous
and cytoplasmic positivity (see Figure 1A–C). Consis-
tent with previous studies of UP2 in various primary
carcinomas,10 we found no staining for UP2 or UP3
in non-urothelial lesions in the TMA of 88 diverse
neoplasms.
H I G H - G R A D E C A R C I N O M A S I N V O L V I N G T H E
B L A D D E R N E C K
We stained whole sections of UC (n = 16) and PCa
(n = 19) involving the bladder neck. UP2 staining
showed significantly greater intensity (P = 0.003)
and proportion (P = 0.03) than UP3 (Table 1). UP2
outperformed UP3, with a sensitivity of 63% versus
19% and specificity of 95% versus 100% (P = 0.02).
Figure 1D–F shows the single focus of UP2 positivity
in PCa of the bladder neck.
H I G H - G R A D E C A R C I N O M A S O F T H E U P P E R T R A C T
We stained a previously reported TMA11 of high-
grade upper tract UCs (n = 19) and renal cell carcino-
mas (clear cell, n = 21 and papillary, n = 21), CDCs
(n = 7), and renal medullary carcinomas (n = 2), as
well as additional whole sections of high-grade upper
tract UCs (n = 10) and CDCs (n = 5). In UC cases,
UP2 showed significantly greater intensity and pro-
portion positive (both P < 0.001), consistent with
increased sensitivity of 68% versus 23% and equal
specificity of 100% (P = 0.006) (Table 1).
M E T A S T A T I C U R O T H E L I A L C A R C I N O M A
We stained 30 whole sections of metastatic urothelial
carcinomas, including metastases to lymph nodes
(n = 11), lung (n = 8), liver (n = 2), stomach/bowel
(n = 4), bone/soft tissue (n = 4) and brain (n = 1). As
before, UP2 staining showed greater intensity and
proportion than UP3 (both P < 0.001), consistent
with higher sensitivity (73% versus 37%, respectively,
P = 0.001); see Table 1. Neither UP2 nor UP3
showed a significant difference in staining between
systemic and nodal metastases (P = 1.0 and
P = 0.43, respectively). Figure 1G–I demonstrates
representative staining in a metastatic UC.
V A R I A N T S O F U R O T H E L I A L C A R C I N O M A
As a descriptive study, we also stained a total of 27
rare variants of UC from the lower tract, finding a
significantly greater intensity and proportion positive
(both P < 0.001) across cases for UP2 versus UP3,
with significantly greater sensitivity (70% versus
19%, respectively, P = 0.001). UP2 positivity was
predominant in plasmacytoid UC (seven of seven), as
well as nested variant (five of five), with one of two
cases of each of the clear cell and small cell variants.
Single cases of micropapillary, villoglandular and
lymphoepithelioma-like UC were each positive, as was
UC with syncytiotrophoblastic giant cells. Sarcoma-
toid (none of three) and ‘chordoid’ UC (none of two)
were uniformly negative, as was a case of UC with
giant-cell rich stromal reaction. Figure 1J–L shows
representative staining of UC variants.
Discussion
Proving urothelial origin for a newly diagnosed carci-
noma has remained a challenge in surgical pathol-
ogy, despite improved markers for demonstrating this
lineage.8,9 We conjecture that this may reflect the
uniquely ‘plastic’ differentiation of the urothelium, as
a histological intermediate between squamous and
columnar epithelia, capable of a remarkable degree of
metaplastic change in physiological, reactive and
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 132–138.
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neoplastic conditions. Until the recent introduction of
antibodies against UP3 with properties serviceable for
routine diagnostic use, this specific property of
urothelial differentiation (urothelial plaques and uro-
plakin expression) could not be harnessed, and even
so has suffered from lack of sensitivity.5,7,8
Table 1. Comparison of uroplakin II (UP2) and uroplakin III (UP3) in diagnostically challenging settings
Diagnostic scenario Epitope Positivity (%) P-value*
Intensity
P-value†
Proportion
P-value†0 1+ 2+ 3+ 0 1+ 2+ 3+
Bladder neck
UC UP2 10/16 (62.5) 0.02 6 – 3 7 0.003 6 1 3 6 0.03
UP3 3/16 (18.8) 13 – 2 1 13 1 – 2
PCa UP2 1/19 (5.2) 18 – – 1 18 1 – –
UP3 0/19 (0) 19 – – – 19 – – –
Upper tract
UC UP2 17/25 (68) 0.006 8 7 4 6 <0.001 8 6 9 2 <0.001
UP3 6/26 (23.1) 20 5 1 – 20 4 2 –
Non-UC UP2 0/50 (0) 50 – – – 50 – – –
UP3 0/49 (0) 49 – – – 49 – – –
Metastatic UC
UP2 22/30 (73.3) 0.001 8 3 11 8 <0.001 8 4 8 10 <0.001
UP3 11/30 (36.7) 19 8 2 1 19 8 3 –
Pattern of variant differentiation in urothelial carcinoma
Plasmacytoid UP2 7/7 (100) 0.001 – 1 1 5 <0.001 – 1 1 5 <0.001
UP3 1/7 (14.2) 6 1 – – 6 – – 1
Nested UP2 5/5 (100) – 1 – 4 – 1 2 2
UP3 2/5 (40) 3 2 – – 3 – 1 1
Sarcomatoid UP2 0/3 (0) 3 – – – 3 – – –
UP3 0/3 (0) 3 – – – 3 – – –
Chordoid UP2 0/2 (0) 2 – – – 2 – – –
UP3 0/2 (0) 2 – – – 2 – – –
Clear cells UP2 1/2 (50) 1 – – 1 1 – – 1
UP3 0/2 (0) – – – – – – – –
Small cell UP2 1/2 (50) 1 1 – – 1 1 – –
UP3 0/2 (0) – – – – – – – –
UC, Urothelial carcinoma; PCa, prostatic carcinoma.
*P-value for test for difference in distributions of binary (positive/negative) UP2 or UP3 status in indicated cases, McNe-
mar’s test.
†P-value for difference in paired distributions in ordinal intensity and proportion scores of UP2 and UP3 stains, Wilcoxon’s
matched-pairs test.
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 132–138.
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Our findings suggest that detection of the related
uroplakin, UP2, provides greater sensitivity with
preserved specificity relative to UP3; indeed, of >160
non-UC tissues studied, only a single case (a poorly
differentiated PCa of the bladder neck) with focal UP2
expression was noted. We note that the superior per-
formance of UP2 is related, to some degree, to the pat-
tern of stain considered positive. The cytoplasmic and
membranous stain of UP2 is more diffuse than the ‘pla-
que-like’ and pericellular membranous stain of UP3;
this results in the increased intensity and proportion of
staining observed. However, pattern aside, the absolute
sensitivity of UP2 was significantly greater than UP3
in each diagnostically challenging setting tested.
Although we would suggest that the primary niche
of uroplakins as markers of urothelial histogenesis
relates to their high specificity, their sensitivity, par-
ticularly that of UP2, deserves consideration in con-
text of the more established urothelial markers. For
instance, among upper tract UCs, where we saw a
sensitivity of 68% for UP2 (23% UP3), both are sub-
stantially less than the 100% sensitivity for p63 and
94% sensitivity of high molecular weight cytokeratin
(HMWCK) seen in the same cohort and reported pre-
viously11 (with the caveat that HMWCK staining was
also positive in 33% of CDCs and 50% of medullary
carcinomas in the cohort). Although p63 was also
100% specific in this same TMA cohort, p63 positiv-
ity has been seen infrequently in CDCs,12 and would
be expected (as would HMWCK expression) in pri-
mary and metastatic squamous lesions. Similarly,
GATA3 expression, although reported to be more sen-
sitive (88%) for upper tract UCs than the 68% we
saw for UP2, has been seen in 6% of CDCs13 and
more than half of chromophobe renal cell carcino-
mas,3 paragangliomas14 and metastatic breast can-
cers and other lesions3 that may be sampled in the
upper tract. In the case of metastases, recent data
support the sensitivity of GATA3 (93%15 compared to
our 73% for UP2), with the same caveats regarding
its expression by squamous and other lesions.3,16,17
Similarly, in the bladder neck, our observation of a
sensitivity of 63% for UP2 staining is inferior to that
reported for HMWCK (97%) and p63 (92%),18 or
even GATA3,16 with the caveat that these markers
are only specific versus PCa but not versus squamous
or other lesions in the bladder neck differential.14,16
In fact, given the advantageously different subcellular
staining patterns for GATA3 and UP2, one might
propose that these two markers be used as a ‘urothe-
lial cocktail’ for biopsies, cytology blocks or other set-
tings with limiting diagnostic material. Our group are
undertaking preliminary efforts in this regard.
Thus, in each of the diagnostic settings we tested,
the result is the same: UP2 outperforms UP3 in terms
of sensitivity, while both are highly specific. While it
bears consideration that neither are as sensitive as
more established markers, our experience is that,
other than uroplakins, no markers have a degree of
specificity sufficient to confirm the diagnosis. The
increased diagnostic performance of UP2 over UP3
may prove to be of great help to surgical pathologists
in these diagnostically challenging settings and in the
setting of limited tissue samples, where performance
of extended immunohistochemical panels is not
feasible.
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